[{"orgOrder":0,"company":"Navamedic","sponsor":"Sensidose","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Navamedic","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Navamedic \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Navamedic \/ Navamedic"},{"orgOrder":0,"company":"Navamedic","sponsor":"Sensidose","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Navamedic","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Navamedic \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Navamedic \/ Navamedic"},{"orgOrder":0,"company":"Navamedic","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Clindamycin Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Navamedic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navamedic \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Navamedic \/ Navamedic"}]

Find Clinical Drug Pipeline Developments & Deals by Navamedic

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.

                          Product Name : Flexilev

                          Product Type : Other Small Molecule

                          Upfront Cash : $9.3 million

                          April 24, 2023

                          Lead Product(s) : Etilevodopa,Carbidopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Sensidose

                          Deal Size : $9.3 million

                          Deal Type : Acquisition

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.

                          Product Name : Flexilev

                          Product Type : Other Small Molecule

                          Upfront Cash : $7.2 million

                          March 29, 2023

                          Lead Product(s) : Etilevodopa,Carbidopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Sensidose

                          Deal Size : $7.2 million

                          Deal Type : Acquisition

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract.

                          Product Name : Clindamycin-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Clindamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : InfoRLife SA

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank